InMed Pharmaceuticals (INM) Cost of Revenue (2021 - 2025)

InMed Pharmaceuticals has reported Cost of Revenue for 5 years, with the latest figure at $635994.0 in Q4 2025.

• On a quarterly basis, Cost of Revenue fell 2.28% year-over-year to $635994.0 in Q4 2025; TTM through Dec 2025 was $3.2 million, a 1.43% increase from a year earlier, with the FY2025 full-year figure at $3.2 million, down 7.46% from the prior year.
• Cost of Revenue was $635994.0 for Q4 2025 at InMed Pharmaceuticals, down from $716962.0 in the prior quarter.
• The five-year high for Cost of Revenue was $1.3 million in Q2 2023, with the low at $127308.0 in Q1 2022.
• Average Cost of Revenue over 5 years is $668484.4, with a median of $728056.0 recorded in 2025.
• The sharpest annual moves came in 2023 and 2024: Cost of Revenue soared 560.93% in 2023, then plunged 37.99% in 2024.
• Over 5 years, Cost of Revenue stood at $153537.0 in 2021, then surged by 120.55% to $338620.0 in 2022, then surged by 170.53% to $916058.0 in 2023, then fell by 28.96% to $650813.0 in 2024, then dropped by 2.28% to $635994.0 in 2025.
• The last three Cost of Revenue figures came in at $635994.0 (Q4 2025), $716962.0 (Q3 2025), and $728056.0 (Q2 2025), per Business Quant data.